Neuroimaging Ancillary Study

CompletedOBSERVATIONAL
Enrollment

184

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

February 14, 2024

Study Completion Date

April 7, 2025

Conditions
Iron Deficiency AnemiaIron Deficiency Anemia of PregnancyNeurodevelopmental Disorder of FoetusIron Deficiency Anemia TreatmentFetal Neurodevelopmental DisorderChild Development
Interventions
DRUG

Ferric carboxymaltose

As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.

DRUG

Iron isomaltoside

As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.

DRUG

Ferric Sulfate

As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.

Trial Locations (1)

Unknown

Jawaharlal Nehru Medical College, Belagavi

All Listed Sponsors
collaborator

Jawaharlal Nehru Medical College

OTHER

lead

Thomas Jefferson University

OTHER